Ratsak is losing its bite: how to get rid of rats in your ranks
New research shows more than half the studied black rats – the most common form of introduced rats in Australia – had a genetic mutation that indicates some resistance to second-generation anticoagulant rodenticides, also known as SGARs.
Black rats are the most common introduced rat in Australia. In Europe, North America and Britain, brown rats have developed resistance to anticoagulant rodenticides. In one UK study, up to half of the observed brown rat population survived repeated ingestion of rat poison.
Experts say the findings are alarming because people might be using larger quantities of poisons to eradicate rats in their homes, thus introducing more poisons into the food chain.
SGARs are so potent that they are lethal to secondary predators that feed on rodents, including tawny frogmouths, Australian boobooks and eastern barn owls.
Loading
Poisons leaching into waterways have also found their way into frogs and toads, while possums and reptiles have also been found to contain SGARs. The poisons work by preventing blood clotting, causing animals to die from internal bleeding.
New research led by Edith Cowan University PhD student and environmental toxicologist Alicia Gorbould found a genetic mutation Tyr25Phe – associated with resistance to anticoagulant rodenticides - in the majority of black rats the team studied.
Gorbould and her colleagues tested the tails of 191 rats caught between 2021 and 2024 in Brisbane, Melbourne, Perth and Sydney.
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
ABC News
2 hours ago
- ABC News
What's in your freezer?
Move the peas over to find that Australian freezers have seals, kangaroo penises and the DNA of 'the Chanel of goats.' Featuring: Dr Natalie Warburton, Murdoch University. Dr Natalie Warburton, Murdoch University. Dr Jillian Garvey, La Trobe University. Dr Jillian Garvey, La Trobe University. Dr Nicola Rivers, Monash University. Dr Nicola Rivers, Monash University. Dianne Hakof, Hospital Manger Animal Health Department Zoos SA Production: Ann Jones, Presenter / Producer. Ann Jones, Presenter / Producer. Petria Ladgrove, Producer. This episode of What the Duck?! was first broadcast in 2022 and was produced on the land of the Wadawarrung and the Kaurna people. Stream the brand-new series Dr Ann's Secret Lives on ABC iview.
AU Financial Review
8 hours ago
- AU Financial Review
World-leading MDMA production kicks off in Australia
Safe, domestically produced MDMA might be the dream for Australian ravers, but it is now a reality for people with treatment-resistant post-traumatic stress disorder after Melbourne-based psychedelics manufacturer Cortexa finished its first production run of 10,000 capsules. In an Australian first, Cortexa has synthesised the world's largest single batch of high-quality therapeutic MDMA, an undertaking two years in the making and produced under high-level security.
The Australian
10 hours ago
- The Australian
CMG enters mobility market as joint health interest accelerates
CMG launches UC-II, a collagen-based supplement for joint mobility Product targets knee pain and stiffness with low-dose, once-daily format Joint health market expanding alongside Australia's ageing population Special Report: Joint pain has become a major focus for Australia's booming complementary medicines industry, now worth more than $6.4 billion a year. As the population ages and demand for non-surgical mobility solutions grows, a number of ASX-listed companies are positioning for growth in the space. Among them are Vita Life Sciences (ASX:VLS), EZZ Life Science (ASX:EZZ), Star Combo Pharma (ASX:S66) and McPhersons (ASX:MCP). While each has its own strategy, the common thread is clear: consumers are spending more on supplements that promise functional outcomes like pain relief, energy support and healthy ageing. Now, Complementary Medicines Group (CMG) is entering the conversation with a new product focused on knees - the part of the body most often linked with mobility decline. Called UC-II, the once-daily capsule contains undenatured type II collagen and has been shown in clinical studies to support joint function, reduce stiffness and improve walking ability in people experiencing mild osteoarthritis or wear-and-tear from an active lifestyle. Dr Brad McEwen PhD, a researcher at CMG, said the formula offered something new for consumers. 'UC-II works by helping the immune system recognise inflammation in the joint and respond appropriately. It targets the underlying cause, not just the symptoms,' he said. 'What makes it unique is the dose. You only need 40 milligrams per day. It is an efficient, well-tolerated alternative to high-dose glucosamine or chondroitin.' Market conditions are shifting Mobility health has emerged as one of the most promising supplement categories in Australia, particularly among people aged 35 and over. More than half of Australian adults use complementary medicines and nearly three in four households report keeping supplements on hand. Pill fatigue, rising interest in preventive health and a growing appetite for clinically validated products are all shaping how consumers choose what to buy. CMG's UC-II has been formulated to address those trends, with supporting evidence from more than a dozen clinical trials. In a six-month study, participants taking UC-II reported improved joint flexibility and reduced pain when climbing stairs, standing upright and walking longer distances. The product is now available through Go Vita stores nationally and is sold under several trusted brand names. Quality and compliance remain key Australia is considered one of the most tightly regulated markets in the world for complementary medicines. All products must be listed on the Australian Register of Therapeutic Goods and adhere to standards set by the Therapeutic Goods Administration. That quality assurance is also a key reason why exports have climbed to more than $1.2 billion per year. For CMG, the goal is not just to enter the category, but to lead with a formulation that is simple, proven and well-positioned for both domestic and export markets. With continued growth in the broader sector and increasing interest in mobility-focused products, the company is hoping UC-II will meet a real and growing need. This article was developed in collaboration with Complementary Medicines Group, a Stockhead advertiser at the time of publishing. This article does not constitute financial product advice. You should consider obtaining independent advice before making any financial decisions.
